top of page
Search

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs


Today, the U.S. Food and Drug Administration published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including psychiatric or substance use disorders. This is the first FDA draft guidance that presents considerations to industry for designing clinical trials for psychedelic drugs.


Kommentare


bottom of page